NCT05228470 · OUTCOME

Overall Survival (OS)

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. · Source last updated 2026-01-06

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: From the date of first dose until death due to any cause. Participants not known to have died were censored on the date of last known alive (up to approximately 37 months)

What was measured

OS was defined as time from date of first dose until death due to any cause.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

anticipated Posting Date: 2026-09
denom Units Selected: Participants
description: OS was defined as time from date of first dose until death due to any cause.
reporting Status: NOT_POSTED
time Frame: From the date of first dose until death due to any cause. Participants not known to have died were censored on the date of last known alive (up to approximately 37 months)
title: Overall Survival (OS)
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice